Depression in children and adolescents: A guide to diagnosis and treatment

Graham J. Emslie, Taryn L. Mayes

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Mood disorders are prevalent and serious disorders in children and adolescents, often causing substantial difficulties in school performance and social relationships. Although the criteria for major depressive disorder are the same for children and adolescents as for adults, some challenges exist in ascertaining the diagnosis. For example, children often have difficulty in expressing or recalling information regarding their disorder; therefore, multiple informants (usually parents) must often be used to obtain the information. In addition, comorbid diagnoses are common in early onset depression, making diagnosis more difficult. However, depression is diagnosable in children and adolescents. The treatment of depression in this population is multi-modal, including the child, parents and school, and is aimed at shortening the episode of depression. Treatment, which is individualised based on need, may include psychotherapy, family therapy or education, and pharmacological treatment. Selective serotonin (5- hydroxytryptamine; 5-HT) reuptake inhibitors are generally the first line of pharmacological treatment in children and adolescents, as they are well tolerated and appear to have fewer adverse effects than antidepressants. As with adults, the majority of children and adolescents with depression do recover within 1 to 2 years; however, recurrence is common. In fact, the recurrence rate is somewhat higher in children and adolescents than in adults. Unfortunately, little research has been done regarding maintenance treatment in children and adolescents. Further research in this area is needed to determine the most effective duration of medication treatment.

Original languageEnglish (US)
Pages (from-to)181-189
Number of pages9
JournalCNS Drugs
Volume11
Issue number3
StatePublished - 1999

Fingerprint

Depression
Serotonin
Therapeutics
Parents
Pharmacology
Recurrence
Family Therapy
Major Depressive Disorder
Mood Disorders
Research
Psychotherapy
Antidepressive Agents
Education
Population

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Neuropsychology and Physiological Psychology

Cite this

Depression in children and adolescents : A guide to diagnosis and treatment. / Emslie, Graham J.; Mayes, Taryn L.

In: CNS Drugs, Vol. 11, No. 3, 1999, p. 181-189.

Research output: Contribution to journalArticle

@article{b69760ca36864b5796e6da22623ef59e,
title = "Depression in children and adolescents: A guide to diagnosis and treatment",
abstract = "Mood disorders are prevalent and serious disorders in children and adolescents, often causing substantial difficulties in school performance and social relationships. Although the criteria for major depressive disorder are the same for children and adolescents as for adults, some challenges exist in ascertaining the diagnosis. For example, children often have difficulty in expressing or recalling information regarding their disorder; therefore, multiple informants (usually parents) must often be used to obtain the information. In addition, comorbid diagnoses are common in early onset depression, making diagnosis more difficult. However, depression is diagnosable in children and adolescents. The treatment of depression in this population is multi-modal, including the child, parents and school, and is aimed at shortening the episode of depression. Treatment, which is individualised based on need, may include psychotherapy, family therapy or education, and pharmacological treatment. Selective serotonin (5- hydroxytryptamine; 5-HT) reuptake inhibitors are generally the first line of pharmacological treatment in children and adolescents, as they are well tolerated and appear to have fewer adverse effects than antidepressants. As with adults, the majority of children and adolescents with depression do recover within 1 to 2 years; however, recurrence is common. In fact, the recurrence rate is somewhat higher in children and adolescents than in adults. Unfortunately, little research has been done regarding maintenance treatment in children and adolescents. Further research in this area is needed to determine the most effective duration of medication treatment.",
author = "Emslie, {Graham J.} and Mayes, {Taryn L.}",
year = "1999",
language = "English (US)",
volume = "11",
pages = "181--189",
journal = "CNS Drugs",
issn = "1172-7047",
publisher = "Adis International Ltd",
number = "3",

}

TY - JOUR

T1 - Depression in children and adolescents

T2 - A guide to diagnosis and treatment

AU - Emslie, Graham J.

AU - Mayes, Taryn L.

PY - 1999

Y1 - 1999

N2 - Mood disorders are prevalent and serious disorders in children and adolescents, often causing substantial difficulties in school performance and social relationships. Although the criteria for major depressive disorder are the same for children and adolescents as for adults, some challenges exist in ascertaining the diagnosis. For example, children often have difficulty in expressing or recalling information regarding their disorder; therefore, multiple informants (usually parents) must often be used to obtain the information. In addition, comorbid diagnoses are common in early onset depression, making diagnosis more difficult. However, depression is diagnosable in children and adolescents. The treatment of depression in this population is multi-modal, including the child, parents and school, and is aimed at shortening the episode of depression. Treatment, which is individualised based on need, may include psychotherapy, family therapy or education, and pharmacological treatment. Selective serotonin (5- hydroxytryptamine; 5-HT) reuptake inhibitors are generally the first line of pharmacological treatment in children and adolescents, as they are well tolerated and appear to have fewer adverse effects than antidepressants. As with adults, the majority of children and adolescents with depression do recover within 1 to 2 years; however, recurrence is common. In fact, the recurrence rate is somewhat higher in children and adolescents than in adults. Unfortunately, little research has been done regarding maintenance treatment in children and adolescents. Further research in this area is needed to determine the most effective duration of medication treatment.

AB - Mood disorders are prevalent and serious disorders in children and adolescents, often causing substantial difficulties in school performance and social relationships. Although the criteria for major depressive disorder are the same for children and adolescents as for adults, some challenges exist in ascertaining the diagnosis. For example, children often have difficulty in expressing or recalling information regarding their disorder; therefore, multiple informants (usually parents) must often be used to obtain the information. In addition, comorbid diagnoses are common in early onset depression, making diagnosis more difficult. However, depression is diagnosable in children and adolescents. The treatment of depression in this population is multi-modal, including the child, parents and school, and is aimed at shortening the episode of depression. Treatment, which is individualised based on need, may include psychotherapy, family therapy or education, and pharmacological treatment. Selective serotonin (5- hydroxytryptamine; 5-HT) reuptake inhibitors are generally the first line of pharmacological treatment in children and adolescents, as they are well tolerated and appear to have fewer adverse effects than antidepressants. As with adults, the majority of children and adolescents with depression do recover within 1 to 2 years; however, recurrence is common. In fact, the recurrence rate is somewhat higher in children and adolescents than in adults. Unfortunately, little research has been done regarding maintenance treatment in children and adolescents. Further research in this area is needed to determine the most effective duration of medication treatment.

UR - http://www.scopus.com/inward/record.url?scp=0032974933&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032974933&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0032974933

VL - 11

SP - 181

EP - 189

JO - CNS Drugs

JF - CNS Drugs

SN - 1172-7047

IS - 3

ER -